PLUS THERAPEUTICS INC
For the period ended Mar 31, 2024. Filed May 15, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 15, 2024
CNSY$0.57-11.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Operations
(in thousands, except share and per share data)
| For the Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Grant revenue | $1,677 | $506 |
| Operating expenses: | ||
| Research and development | 2,763 | 2,983 |
| General and administrative | 2,213 | 2,245 |
| Total operating expenses | 4,976 | 5,228 |
| Operating loss | (3,299) | (4,722) |
| Other income (expense): | ||
| Interest income | 72 | 51 |
| Interest expense | (34) | (134) |
| Total other expense | 38 | (83) |
| Net loss | $(3,261) | $(4,805) |
| Net loss per share, basic and diluted | $(0.75) | $(2.07) |
| Basic and diluted weighted average shares used in calculating net loss per share attributable to common stockholders | 4,321,731 | 2,320,017 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.